HAE in the News

The articles listed below are various press releases on Hereditary Angioedema

---

Page#:  1  2  3  4  5  6  7  8  9  10 


Pharming Sites Obtain GMP Status for Production of Drug against Hereditary Angioedema
Pharming reports that its facilities for the manufacturing of Rhucin® have successfully passed the EMEA’s inspections. The drug is being developed to treat acute attacks of hereditary angioedema. ...more


Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
Lev Pharmaceuticals, Inc. ... today announced it has completed the formation of its marketing and sales management team. ...more


Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTC: LEVP) (BULLETIN BOARD: LEVP) announced today that it has completed patient treatment in the prophylactic portion of its Phase III clinical trial of C1-esterase inhibitor ...more


Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Dyax Corp. (Nasdaq:DYAX) announced today that patient treatment has begun in the Phase 2 trial of DX-88 (ecallantide) for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which includes coronary artery bypass graft (CABG) surgery and heart valve replacement or repair procedures. ...more


Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Dyax Corp. (Nasdaq:DYAX) announced today that patient treatment has begun in the Phase 3 confirmatory trial, known as EDEMA4, for its lead product candidate, DX-88 (ecallantide). ...more


DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Dyax Corp. (Nasdaq:DYAX - News) announced today positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). ...more


Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)
To assess whether the selective bradykinin receptor-2 antagonist Icatibant is effective in acute edema attacks of hereditary angioedema...In hereditary angioedema, bradykinin is assumed to be the most important mediator of edema ...more


Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
Lev Pharmaceuticals, Inc. (Lev) (OTC Bulletin Board: LEVP - News) today announced positive results from its pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH) for the acute treatment of hereditary angioedema (HAE). ...more


CSL Behring Launches New Online Resource for Patients With Hereditary Angioedema, a Rare and Serious Disorder
Patients with a rare disease called Hereditary Angioedema (HAE) -- and their doctors -- can now find comprehensive information ...more


CSL inhibitor effective against rare blood disease
A new study has revealed that CSL Behring's C1-inhibitor concentrate is highly effective and safe in treating skin swelling in patients with hereditary angioedema. ...more


Page #:  1  2  3  4  5  6  7  8  9  10 

The US Hereditary Angioedema Assoc., Seven Waterfront Plaza, 500 Ala Moana Blvd., Suite 400, Honolulu, HI 96813, (866) 798-5598

The US HAEA's 2010 corporate sponsors